We're Here For You | (877) 205-6480

Press Release

More info…
Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) (Peg …

drug use

Posted in Nationwide Drug Intervention  |  Leave a comment

Leave a reply

We’re Here For You